Hydroxychloroquine, Drugs Monitor, Page 2

(24 Feb 2021) Hydroxychloroquine & Azithromycin- ineffective in hospitalized patients with mild to moderate COVID-19

March 1, 2021

Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 https://doi.org/10.1016/j.bjid.2021.101549 The active group comprised 101 (52.3%) patients using hydroxychloroquine associated with azithromycin and the control group 92 (47.7%) patients who did not take these medications. Median age was… Continue reading "(24 Feb 2021) Hydroxychloroquine & Azithromycin- ineffective in hospitalized patients with mild to moderate COVID-19"

(23 Feb 2021) Ivermectin & Hydroxychloroquine- neither of them decreases the number of in-hospital days

March 1, 2021

Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial https://www.medrxiv.org/content/10.1101/2021.02.18.21252037v1 NCT04391127–During the month of August, the admission of patients requiring hospitalization mostly encompassed cases with severe respiratory failure, so we ended the recruitment… Continue reading "(23 Feb 2021) Ivermectin & Hydroxychloroquine- neither of them decreases the number of in-hospital days"

(19 Feb 2021) Hydroxychloroquine- associated with increased risks of ICU admission

March 1, 2021

Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection https://doi.org/10.1093/ajhp/zxab056 A retrospective, observational, cohort study was conducted to determine selected treatment outcomes in 336 patients hospitalized with COVID-19 at an acute care, community hospital in… Continue reading "(19 Feb 2021) Hydroxychloroquine- associated with increased risks of ICU admission"

(05 Feb 2021) Hydroxychlooquine- No beneficial effect or significant harm

February 16, 2021

HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIAL https://www.medrxiv.org/content/10.1101/2021.02.01.21250371v1 NCT04315896- A total of 214 patients with COVID-19 were recruited, randomized and analyzed. They were hypoxemic with a mean SpO2 of 65% ± 20, tachycardic… Continue reading "(05 Feb 2021) Hydroxychlooquine- No beneficial effect or significant harm"

(16 Jan 2021) Hydroxychloroquine- associated with a decreased rate of subsequent hospitalization

January 19, 2021

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study https://doi.org/10.1186/s12879-021-05773-w Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were… Continue reading "(16 Jan 2021) Hydroxychloroquine- associated with a decreased rate of subsequent hospitalization"

(23 Dec 2020) Hydroxychloroquine- HCQ was associated with a slower viral clearance in mild to moderateCOVID-19 patients

December 28, 2020

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease https://doi.org/10.1097/MD.0000000000023720 Thirty-four confirmed COVID-19 patients completed the study. Nineteen (55.9%) patients presented with symptoms, and 14 (41.2%) had pneumonia. Only 21 (61.8%) patients received… Continue reading "(23 Dec 2020) Hydroxychloroquine- HCQ was associated with a slower viral clearance in mild to moderateCOVID-19 patients"

(22 Dec 2020) Hydroxychloroquine- early stage use decreased the improvement time

December 28, 2020

Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China https://doi.org/10.5582/bst.2020.03340 A total of 616 patients, including 50 (8.11%) severe and 18 (2.92%) critical patients, were enrolled in our retrospective cohort study. The early use… Continue reading "(22 Dec 2020) Hydroxychloroquine- early stage use decreased the improvement time"

(09 Dec 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 infection

December 14, 2020

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 https://doi.org/10.1056/NEJMoa2021801 An open-label, cluster-randomized trial (NCT04304053) involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome… Continue reading "(09 Dec 2020) Hydroxychloroquine- Postexposure therapy with HCQ did not prevent SARS-CoV-2 infection"

(08 Dec 2020) Hydroxychloroquine- not found beneficial for postexposure prophylaxis

December 14, 2020

Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial https://doi.org/10.7326/M20-6519 Household-randomized, double-blind, controlled trial of hydroxychloroquine postexposure prophylaxis. (ClinicalTrials.gov: NCT04328961). SETTING: National U.S. multicenter study. PARTICIPANTS: Close contacts recently exposed (<96 hours)… Continue reading "(08 Dec 2020) Hydroxychloroquine- not found beneficial for postexposure prophylaxis"

(03 Dec 2020) Solidarity trials- RDV, HCQ, LPV & IFN regimens had little or no effect on hospitalized patients with Covid-19

December 5, 2020

Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results https://doi.org/10.1056/NEJMoa2023184 At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including… Continue reading "(03 Dec 2020) Solidarity trials- RDV, HCQ, LPV & IFN regimens had little or no effect on hospitalized patients with Covid-19"

Tag: Hydroxychloroquine